Translate Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
07 mai 2020 16h26 HE
|
Translate Bio, Inc.
-- Pursuing development of mRNA vaccine against COVID-19 through expanded collaboration with Sanofi Pasteur -- -- Existing large-scale manufacturing capacity expected to help meet needs of...
Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19
27 mars 2020 02h00 HE
|
Translate Bio, Inc.
The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development PARIS and LEXINGTON, Mass., March 27,...
Translate Bio Provides MRT5005 Program Updates
26 mars 2020 16h30 HE
|
Translate Bio, Inc.
-- FDA grants Rare Pediatric Disease designation for MRT5005 for treatment of cystic fibrosis – -- Response to COVID-19 pandemic anticipated to cause interruptions in certain clinical trial...
Translate Bio Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Progress
12 mars 2020 16h45 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosis
26 févr. 2020 07h30 HE
|
Translate Bio, Inc.
-- First inhaled mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020 -- LEXINGTON,...
Translate Bio to Present at Upcoming Investor Conferences
19 févr. 2020 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Executive Leadership Appointments
12 déc. 2019 16h15 HE
|
Translate Bio, Inc.
-- Appointment of Frank DeRosa, Ph.D. to Chief Technology Officer, and transition of Michael Heartlein, Ph.D. to Executive Vice President and Founder -- -- Appointment of Paul Burgess to Chief...
Translate Bio to Present at Upcoming Investor Conferences
13 nov. 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Announces Third Quarter 2019 Financial Results and Reviews Recent Highlights
06 nov. 2019 16h11 HE
|
Translate Bio, Inc.
-- Advanced CF program with single-ascending dose (SAD) clinical data presentation and continued enrollment and dosing in multiple-ascending dose (MAD) portion of Phase 1/2 trial -- -- Prioritized...
Translate Bio Presents MRT5005 Data at the 33rd Annual North American Cystic Fibrosis Conference
31 oct. 2019 12h15 HE
|
Translate Bio, Inc.
NASHVILLE, Tenn., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...